Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BHV-1100 + CIML NK cells
- Development stage
- Unknown
- Lead developer
- Biohaven
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**BHV-1100 + CIML NK cells** is a combination therapy for multiple myeloma (MM) consisting of BHV-1100, a fully synthetic bispecific antibody-recruiting molecule (ARM) that binds CD38 on MM cells and endogenous immunoglobulin (Ig) to recruit natural killer (NK) cells for antibody-dependent cellular cytotoxicity (ADCC), paired with autologous cytokine-induced memory-like (CIML) NK cells primed with IL-12, IL-15, and IL-18 and coated with BHV-1100 ("ARMored") to enhance tumor killing without fratricide. Developed by Biohaven, this regimen is administered as a single-dose infusion post-melphalan conditioning and prior to autologous stem cell transplant (ASCT) in MRD-positive patients in first remission, often with IVIG and low-dose IL-2; preclinical data show superior ex vivo killing of MM cells (e.g., 90.8% vs. 81% at 24h), increased IFNγ and CD107a, with in vivo persistence peaking at day 28.[1][3][5]
- Other names
- BHV-1100 plus cytokine induced memory-like NK cells plus IVIG and low dose IL-2BHV1100 plus cytokine induced memory-like NK cells plus IVIG and low dose IL-2BHV 1100 plus cytokine induced memory-like NK cells plus IVIG and low dose IL-2
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on BHV-1100 + CIML NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHV-1100 + CIML NK cells.